With chronic kidney disease projected to be the fifth leading cause of death by 2040, Nephrologist Dr. Adrian Sawyer is ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

Medically reviewed by Mary Choy, PharmD It can be surprising to learn that a medication you’re taking for one condition may ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

HALF a million Brits with deadly high blood pressure could be cured by a transformative new treatment. Doctors from the UK ...

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Acute kidney injury (AKI) and vitamin D deficiency have a bi-directional relationship. Patients with sepsis AKI might be helped by vitamin D supplementation.

Casarosa pointed to aldosterone synthase inhibitor BI 690517 ... as well as TRPC6 inhibitor BI 764198 in phase 2 for rare kidney disease focal segmental glomerulosclerosis (FSGS).